Is Progesterone (Luteal Support) Safe While Trying to Conceive?

What Exactly Is Luteal Phase Support, and Why Do Women Need It?

The luteal phase is the second half of your menstrual cycle, the roughly 14 days between ovulation and either your period or a positive pregnancy test. During those days, the corpus luteum, the temporary glandular structure left behind after ovulation, secretes progesterone. Progesterone prepares the uterine lining (endometrium) for implantation, suppresses uterine contractions, and signals to your body that a pregnancy may be underway.

In a natural, unassisted cycle, the corpus luteum usually does its job adequately. But several situations disrupt that process enough to matter clinically.

When the Luteal Phase Falls Short

A luteal phase defect, defined loosely as inadequate progesterone secretion or endometrial response in the post-ovulatory phase, has been linked to recurrent implantation failure and early pregnancy loss in some women. The exact prevalence is debated, but one systematic review found luteal phase defects in up to 8 to 28 percent of women with recurrent miscarriage, depending on the diagnostic criteria used.

In IVF and other assisted reproductive technology (ART) cycles, the problem is more clear-cut. Ovarian stimulation with gonadotropins suppresses the pituitary through a feedback loop. The GnRH agonists or antagonists used to prevent premature LH surges further blunt luteal function. The result: after egg retrieval, the corpus luteum is functionally impaired and serum progesterone levels fall sharply without supplementation, making exogenous luteal support not optional but essential.

Forms of Progesterone Used for Luteal Support

Luteal support can be delivered vaginally, intramuscularly, or orally. Vaginal micronized progesterone is the most widely used route in the United States and Europe because it achieves high local endometrial concentrations while causing fewer systemic side effects than intramuscular progesterone-in-oil. The FDA-approved products for luteal support include:

• Crinone 8% gel (progesterone 90 mg) applied vaginally once daily
• Endometrin 100 mg vaginal insert used two to three times daily
• Prometrium 200 mg capsule (micronized progesterone oral/vaginal), sometimes inserted vaginally off-label

This article focuses on vaginal micronized progesterone because it is the dominant clinical form and the one most women using fertility treatment will encounter.

Is Vaginal Micronized Progesterone Safe While Trying to Conceive?

Yes. Vaginal micronized progesterone has one of the longest safety records of any drug used in reproductive medicine. Decades of use in IVF programs globally, combined with multiple large randomized controlled trials, have not identified a signal for fetal harm, maternal harm, or increased miscarriage risk attributable to the drug itself.

What the Human Data Actually Show

The most cited evidence base comes from IVF trials where progesterone supplementation was compared to no supplementation or to alternative formulations. A 2021 Cochrane review of 101 randomized trials involving more than 16,000 women concluded that vaginal progesterone improves live birth rates in IVF cycles compared to no luteal support, with no increase in miscarriage, ectopic pregnancy, or congenital anomaly rates.

ASRM's Practice Committee guidelines state plainly that progesterone supplementation is required for luteal phase support in all IVF/ICSI cycles because of the known impairment of corpus luteum function following controlled ovarian stimulation.

In natural and stimulated intrauterine insemination (IUI) cycles, the picture is more nuanced. A 2022 randomized trial published in NEJM (the REPROTOX-IUI study) found that vaginal progesterone after IUI significantly increased ongoing pregnancy rates at 12 weeks compared to no treatment, 33 percent versus 28 percent (p = 0.003). That 5-percentage-point absolute improvement is modest but clinically real, and no safety concerns emerged.

Animal Data and What Gets Extrapolated

Progestins as a class raised concern decades ago when older, synthetic progestins were associated with virilization of female fetuses in some animal models. Micronized progesterone is bioidentical, meaning its chemical structure is identical to the progesterone your own ovaries make. Animal studies conducted with micronized progesterone have not replicated the teratogenic findings seen with synthetic progestins. Human registries and post-marketing surveillance have not identified an increased rate of any specific congenital anomaly. Be honest with yourself about where the data thin out: long-term neurodevelopmental outcomes in children born after progesterone supplementation are not comprehensively studied, and that gap is worth knowing.

Dosing Across Fertility Treatment Scenarios

Doses vary by clinical situation. Using the wrong dose or timing, or stopping abruptly too early in pregnancy, can matter.

IVF and Frozen Embryo Transfer Cycles

For fresh IVF cycles, vaginal progesterone typically starts on the day of oocyte retrieval or the day after. Standard regimens include:

• Crinone 8% gel 90 mg vaginally once daily
• Endometrin 100 mg vaginally two to three times daily

Both achieve endometrial progesterone concentrations roughly 10 to 14 times higher than serum concentrations, a pharmacokinetic advantage called the "first uterine pass effect" that makes vaginal delivery particularly suited to luteal support.

For frozen embryo transfer (FET) cycles using a programmed (artificial) protocol, the endometrium is prepared with estradiol first, and progesterone is typically added 5 to 6 days before a day-5 blastocyst transfer. Timing precision here is critical: a 2019 study in Fertility and Sterility found that the window of implantation shifts if progesterone exposure starts even one day late, reducing live birth rates.

Natural and Stimulated IUI Cycles

Dosing in IUI cycles is less standardized. Many reproductive endocrinologists use Crinone 8% once daily or Endometrin 100 mg twice daily starting on the day of IUI or the day after, continuing for 14 to 16 days until a pregnancy test. If the test is positive, treatment continues.

Natural Conception with Recurrent Pregnancy Loss

For women with recurrent pregnancy loss (RPL) trying to conceive naturally, the evidence picture is more complex. The PRISM trial (2019, Lancet) randomized 4,153 women with early pregnancy bleeding to vaginal progesterone 400 mg twice daily or placebo and found no overall benefit. A prespecified subgroup analysis, however, did show a significant benefit in women with three or more prior pregnancy losses: live birth rate 72 percent versus 57 percent. The PRISM authors and subsequent ACOG commentary flagged this as hypothesis-generating rather than definitive, but many RPL specialists now offer progesterone to this specific subgroup.

Pregnancy and Lactation Safety

This section applies whether you are in fertility treatment or have conceived naturally and your provider is recommending progesterone to support early pregnancy.

Use During Early Pregnancy

Micronized progesterone is not teratogenic based on available human data. No pattern of congenital malformations has been established. The FDA label for Endometrin states that animal reproductive studies do not always predict human response, and that there are no adequate and well-controlled studies in pregnant women for most progesterone products, though decades of observational use in IVF pregnancies provide substantial reassurance.

Progesterone is typically continued through 8 to 10 weeks of gestation in IVF pregnancies, at which point the placenta takes over progesterone production (the luteal-placental shift). Stopping earlier than 8 weeks without provider guidance carries a theoretical risk of progesterone withdrawal in a corpus-luteum-dependent early pregnancy.

Do not stop progesterone abruptly if you become pregnant during a treatment cycle without first speaking to your reproductive endocrinologist. Sudden discontinuation before the luteal-placental shift may destabilize early pregnancy support.

Breastfeeding and Lactation

If you are not currently pregnant and are asking about progesterone while breastfeeding (for example, if you are trying to conceive again postpartum), the safety profile is reassuring but data are limited.

LactMed (NIH's drug and lactation database) notes that progesterone passes into breast milk in small amounts. Endogenous progesterone is present in breast milk naturally throughout lactation. Exogenous micronized progesterone adds modestly to that baseline. LactMed concludes there is no evidence of harm to nursing infants from maternal progesterone supplementation, though the data set is thinner than most clinicians would prefer.

One practical consideration: high-dose exogenous progesterone, particularly oral or intramuscular formulations, may suppress prolactin-dependent milk production in some women. Vaginal administration, with its lower systemic absorption, is less likely to affect milk supply than oral or IM routes, but this has not been studied in a controlled trial. If you are breastfeeding and TTC simultaneously, tell your prescriber. They can factor milk supply into the route-of-administration choice.

Contraception Requirement

None. Progesterone for luteal support is prescribed specifically to help you achieve or maintain a pregnancy. No contraception is needed, and none is appropriate during this treatment.

Who This Is Right For (and Who Should Reconsider)

Not every woman trying to conceive needs supplemental progesterone. Prescribing it without a clear indication adds cost, inconvenience, and the small psychological burden of daily vaginal medication with no demonstrated benefit.

Women Most Likely to Benefit

• IVF or ICSI cycles. Luteal support is standard of care. You should expect it to be prescribed. ASRM guidelines give this a Grade A recommendation.
• Frozen embryo transfer (programmed protocol). Your endometrium has no corpus luteum at all. Progesterone is the only source of luteal-phase hormone.
• Women with three or more prior miscarriages. Based on the PRISM subgroup data, many RPL specialists offer a trial of vaginal progesterone in subsequent pregnancies. Discuss with an RPL specialist rather than self-prescribing.
• IUI cycles. Evidence supports a modest improvement in ongoing pregnancy rate (NEJM 2022 data cited above).
• Documented luteal phase defect. If your provider has confirmed a short luteal phase or consistently low mid-luteal serum progesterone (typically below 10 ng/mL), supplementation is a reasonable clinical choice.

Women for Whom Benefit Is Less Certain

• Women with regular cycles, no prior pregnancy loss, and no fertility treatment. There is no evidence that empiric progesterone supplementation improves natural conception rates in this group.
• Women with one prior early miscarriage. The PRISM trial found no benefit in the broader group with one or two prior losses.
• Women with unexplained infertility but normal luteal function on serum testing. Supplementation may be offered, but the evidence is weaker and your provider should explain the rationale.

Sex-Specific Physiology: How Your Cycle and Hormonal Status Change Everything

Progesterone does not act in isolation. Its effects on your body depend on your estrogen status, where you are in your menstrual cycle, and whether you are in a natural or medicated cycle.

The Estrogen Priming Requirement

Progesterone receptors in the endometrium are upregulated by estrogen. Without adequate estrogen exposure in the follicular phase, progesterone cannot produce a fully receptive endometrium even at high doses. This is why programmed FET cycles always begin with estradiol supplementation for 10 to 14 days before progesterone is introduced. A 2020 study in the Journal of Clinical Endocrinology and Metabolism confirmed that endometrial progesterone receptor expression correlates strongly with prior estrogen exposure, not just progesterone dose.

PCOS and Luteal Phase Considerations

Women with polycystic ovary syndrome (PCOS) often have irregular ovulation, and when they do ovulate, the corpus luteum may be suboptimal. ASRM's 2023 PCOS guideline notes that women with PCOS undergoing ovulation induction with gonadotropins have a particularly high rate of corpus luteum dysfunction and should generally receive luteal support. If you have PCOS and are doing IUI with gonadotropins, ask specifically about progesterone support rather than assuming it will be offered automatically.

Perimenopause and Trying to Conceive

Women in their late 30s and early 40s who are trying to conceive while experiencing perimenopausal hormonal changes may have shorter, more erratic luteal phases. Perimenopause does not automatically mean infertility, but the corpus luteum function in this life stage is more variable than in the reproductive peak years. A study in Menopause journal (2019) documented significantly shorter luteal phases and lower mid-luteal progesterone levels in perimenopausal women compared to women in their mid-reproductive years. If you are 40 or older and TTC, discuss whether mid-luteal progesterone testing and possible supplementation makes sense for your cycle even before starting formal fertility treatment.

Side Effects Specific to Women Using Vaginal Progesterone

Vaginal micronized progesterone has a different side-effect profile than oral or intramuscular forms, and knowing what to expect reduces unnecessary anxiety during an already stressful time.

Common and Expected

• Vaginal discharge. Crinone gel in particular accumulates as a white to pale yellow residue. This is the gel vehicle, not an infection. It is normal and does not need treatment.
• Vaginal irritation or spotting. Light spotting during the two-week wait after embryo transfer or IUI is common and does not reliably indicate miscarriage or success.
• Breast tenderness. Progesterone-driven, and mirrors what many women feel in the late luteal phase of a natural cycle.
• Bloating and mild pelvic pressure. Common, especially in IVF cycles where the ovaries are also enlarged from stimulation.

Less Common but Worth Knowing

• Drowsiness. Vaginal administration produces lower systemic progesterone levels than oral Prometrium, so sedation is less pronounced, but some women notice mild fatigue, particularly at higher doses.
• Mood changes. Progesterone metabolizes to allopregnanolone, a neurosteroid that modulates GABA receptors. Some women are highly sensitive to this and notice low mood, anxiety, or irritability. Vaginal administration blunts but does not eliminate this effect.

What Vaginal Progesterone Does NOT Cause

It does not cause ovarian hyperstimulation syndrome (OHSS) on its own, does not increase your risk of ectopic pregnancy, and does not delay the recognition of a failed cycle once you stop taking it. Your period or beta-HCG result will clarify outcome within a few days of stopping.

Monitoring and What to Expect Clinically

Most reproductive endocrinology practices monitor serum progesterone levels during IVF cycles to confirm adequate absorption, though a 2021 study in Human Reproduction found that serum progesterone on the day of embryo transfer (target above 10 nmol/L with some protocols targeting above 20 nmol/L) predicts live birth rates better than dose alone. If your serum level is below the target despite standard vaginal dosing, your provider may add intramuscular progesterone-in-oil or switch protocols.

As WomanRx medical reviewer Dr. Elena Vasquez, MD, notes: "One thing I make sure every patient understands before starting a vaginal progesterone protocol is that a negative pregnancy test after a two-week wait does not mean the progesterone failed. It means this cycle did not result in implantation, which is a normal part of fertility treatment even with excellent protocols. Stopping progesterone at that point and waiting for the next cycle is exactly right, not a failure."

In natural TTC cycles where progesterone is being used for luteal phase defect or recurrent loss, monitoring is less intensive. A serum progesterone drawn 7 days after confirmed ovulation (day 21 in a 28-day cycle, but ideally timed to 7 days post-ovulation rather than a calendar date) should ideally exceed 10 ng/mL, with levels above 15 ng/mL generally considered reassuring for an ongoing pregnancy.

Evidence Gaps and What Is Still Uncertain

Women deserve honest acknowledgment of what we do not yet know.

The evidence for luteal support in IVF is strong and consistent. The evidence for luteal support in IUI is moderate and improving (the NEJM 2022 trial was a significant addition). The evidence for luteal support in natural TTC cycles without documented defect or RPL is weak and does not currently support routine use.

Long-term pediatric outcomes after progesterone exposure in the first trimester have not been studied in adequately powered, prospectively designed trials. The reassurance we have comes from decades of observational follow-up in IVF cohorts, which is meaningful but not equivalent to a dedicated safety registry. The ESHRE working group on safety in ART called in 2020 for dedicated pediatric follow-up registries for all hormonal exposures in early pregnancy, and that work is ongoing.

Women of color and women with chronic conditions including autoimmune disease, thyroid disorders, and insulin resistance have been underrepresented in luteal support trials. Extrapolation of standard dosing and efficacy data to these groups is reasonable but not directly validated.